Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine tablets, usp are indicated for the treatment of schizophrenia. the efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). the effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies (14.1) ]. quetiapine tablets, usp are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see clinical studies (14.2) ]. quetiapine tablets, usp are indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine fumarate tablets are indicated for the treatment of schizophrenia. the efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6 week trials in adults. the effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies (14.1)]. pediatric use information in patients (13 to 17 years of age) with schizophrenia is approved for astrazeneca pharmaceuticals lp’s quetiapine fumarate drug product labeling. however, due to astrazeneca pharmaceuticals lp’s marketing exclusivity rights; this drug product is not labeled for use in those adolescent patients. quetiapine fumarate tablets are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12 week monotherapy trials in adults, in one 3 week adjunctive trial in adults [see clinical studies

Airija - anglų - HPRA (Health Products Regulatory Authority)

piramal critical care limited - fentanyl citrate - solution for injection - 50 microgram(s)/millilitre - opioid anesthetics; fentanyl

Airija - anglų - HPRA (Health Products Regulatory Authority)

piramal critical care b.v. - fentanyl citrate - solution for injection - 50 microgram(s)/millilitre - opioid anesthetics; fentanyl

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine is indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies ( 14.1)]. quetiapine is indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see clinical studies ( 14.2)]. quetiapine is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials in adult pa

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mylan institutional llc - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil injection, usp is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil  injection  is  indicated  for  the  reversal  of  conscious  sedation  induced with benzodiazepines (see precautions : pediatric use ). flumazenil injection, usp is contraindicated: flumazenil acts as a benzodiazepine antagonist, blocks the effects of benzodiazepines in animals and man, antagonizes benzodiazepine reinforcement in animal models, produces dysphoria in normal subjects, and has had no reported abuse in foreign marketing. although flumazenil has a benzodiazepine-like structure it does not act as a benzodiazepine agonist in man and is not a controlled substance.

Airija - anglų - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - sodium chloride; glucose monohydrate ph. eur.; sodium acetate, trihydrate; potassium chloride ph. eur.; magnesium chloride hexahydrate ph. eur. - solution for infusion - 55.00 gram(s)/litre - electrolytes with carbohydrates

Malta - anglų - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - glucose anhydrous, sodium chloride, sodium acetate, trihydrate, potassium chloride, magnesium chloride, hexahydrate - solution for infusion - glucose anhydrous 50 g sodium chloride 1 g sodium acetate trihydrate 3.13 g potassium chloride 1.5 g magnesium chloride hexahydrate 0.30 g - blood substitutes and perfusion solutions

Airija - anglų - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - fentanyl citrate - solution for injection - 50 microgram/ml - opioid anesthetics

Kanada - anglų - Health Canada

baxter corporation clintec nutrition division - l-proline; l-tyrosine; sodium acetate; potassium phosphate dibasic; sodium chloride; magnesium chloride; tryptophan; dextrose; l-leucine hydrochloride; l-phenylalanine hydrochloride; l-lysine hydrochloride; methionine; l-alanine; glycine; l-arginine; l-isoleucine; l-valine; histidine; l-threonine - solution - 105mg; 10mg; 170mg; 130.5mg; 29.3mg; 25.5mg; 45mg; 10g; 155mg; 155mg; 145mg; 145mg; 520mg; 520mg; 260mg; 120mg; 115mg; 110mg; 10 - l-proline 105mg; l-tyrosine 10mg; sodium acetate 170mg; potassium phosphate dibasic 130.5mg; sodium chloride 29.3mg; magnesium chloride 25.5mg; tryptophan 45mg; dextrose 10g; l-leucine hydrochloride 155mg; l-phenylalanine hydrochloride 155mg; l-lysine hydrochloride 145mg; methionine 145mg; l-alanine 520mg; glycine 520mg; l-arginine 260mg; l-isoleucine 120mg; l-valine 115mg; histidine 110mg; l-threonine 105mg - caloric agents